- Home
- CNTX vs NSPR Comparison
CNTX vs NSPR Comparison
Compare CNTX & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- NSPR
- Stock Information
- Founded
- CNTX 2015
- NSPR 2005
- Country
- CNTX United States
- NSPR United States
- Employees
- CNTX N/A
- NSPR N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- CNTX Health Care
- NSPR Health Care
- Exchange
- CNTX Nasdaq
- NSPR Nasdaq
- Market Cap
- CNTX 78.0M
- NSPR 74.8M
- IPO Year
- CNTX 2021
- NSPR N/A
- Fundamental
- Price
- CNTX $0.79
- NSPR $2.50
- Analyst Decision
- CNTX Strong Buy
- NSPR Strong Buy
- Analyst Count
- CNTX 5
- NSPR 2
- Target Price
- CNTX $5.25
- NSPR $4.50
- AVG Volume (30 Days)
- CNTX 145.6K
- NSPR 109.7K
- Earning Date
- CNTX 08-06-2025
- NSPR 08-05-2025
- Dividend Yield
- CNTX N/A
- NSPR N/A
- EPS Growth
- CNTX N/A
- NSPR N/A
- EPS
- CNTX N/A
- NSPR N/A
- Revenue
- CNTX N/A
- NSPR $7,066,000.00
- Revenue This Year
- CNTX N/A
- NSPR $4.85
- Revenue Next Year
- CNTX N/A
- NSPR $113.47
- P/E Ratio
- CNTX N/A
- NSPR N/A
- Revenue Growth
- CNTX N/A
- NSPR 7.60
- 52 Week Low
- CNTX $0.49
- NSPR $1.99
- 52 Week High
- CNTX $2.70
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- CNTX 58.08
- NSPR 51.38
- Support Level
- CNTX $0.68
- NSPR $2.37
- Resistance Level
- CNTX $0.73
- NSPR $2.60
- Average True Range (ATR)
- CNTX 0.05
- NSPR 0.19
- MACD
- CNTX -0.00
- NSPR -0.01
- Stochastic Oscillator
- CNTX 55.65
- NSPR 25.86
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.